Tackling fibrosis, increasing healthspan

GAT Therapeutics is an early stage biopharma targeting orphan fibrotic diseases

Tackling fibrosis, increasing healthspan

GAT Therapeutics is an early stage biopharma targeting fibrosis and age-related diseases.

Pipeline

.

GTX-011 is a novel TGF-β pathway modulator. We believe it has the potential to become mainstay therapy for orphan fibrotic diseases.

Team

Our scientists partner with leading researchers and clinicians to translate discoveries into patient outcomes.

Jaume

CEO

Noemí

CMC Manager

Eugenia

CSO

Joan

CBO

News

2022 | PRESS RELEASE

GTX-011 expanding potential in lung fibrosis

GAT Therapeutics teams up with IDIBELL to validate GTX-011 potential in interstitial lung diseases. Promising preclinical results will be presented at the ERS annual congress and at the ICLAF meeting.

2021 | PRESS RELEASE

GAT Therapeutics validates GTX-011 antifibrotic efficacy in liver

GAT Therapeutics presents very promising preclinical results of GTX-011 in models of advanced hepatic fibrotic disease at the EASL summit and at the AASLD meeting. Data was obtained in collaboration with Barcelona Liver Bioservices (BLB).

2020 | SEED FUNDING

GAT Therapeutics secures 4 Million

GAT Therapeutics secures 4 Million EUR in seed financing from current investors and public funding programs to accelerate the preclinical development of its leading drug candidate GTX-011 targeting fibrosis.

Contact us

Privacy Policy

Parc Científic de Barcelona
C/Baldiri Reixac 4
08028 Barcelona (Spain)

info@gattx.com

Terms of use
Privacy statement
Cookies policy
Funding

2020 I GAT Therapeutics. All rights reserved